SBMFF
Sino Biopharmaceutical Limited
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
0.75
▲ 0.10 (15.21%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.75
Prev close
0.65
Day high
0.65
Day low
0.65
Volume
1.00K
Market cap
$13.33B
P/E (TTM)
37.50
52W range
0.59 – 1.24
Day trading desk
Gap from prior close
+15.21%
Prior close 0.65
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
0.75 – 0.75
Position in range
—
—
ATR (14D)
0.01
1.59% of price
Prior day high
0.65
PDH
Prior day low
0.65
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 717
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+22.95%
+24.3%
1M
+17.74%
+14.0%
3M
+8.38%
+5.3%
6M
-10.71%
-21.8%
YTD
-13.99%
-26.3%
1Y
-24.17%
-44.2%
3Y
+92.31%
+18.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SBMFF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.68B
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 30, 26 | Cheng (Cheung Ling) Director (Executive) |
BUY | 1.00M | $695.80K | Direct |
| Apr 29, 26 | Cheng (Cheung Ling) Director (Executive) |
BUY | 1.00M | $698.00K | Direct |
| Apr 29, 26 | Tse (Ping) Director (Executive) |
BUY | 2.00M | $1.41M | Direct |
| Apr 28, 26 | Cheng (Cheung Ling) Director (Executive) |
BUY | 3.00M | $2.08M | Direct |
| Mar 31, 26 | Tse (Ping) Director (Executive) |
BUY | 3.50M | $2.62M | Direct |
| Mar 30, 26 | Tse (Theresa Y Y) Chairman of the Board |
BUY | 1.75M | $1.28M | Direct |
| Dec 24, 25 | Tse (Hsin Stephen) Director (Executive) |
BUY | 1.00M | $824.00K | Direct |
| Aug 20, 25 | Tse (Hsin Stephen) Director (Executive) |
BUY | 1.00M | $943.10K | Direct |
| Aug 20, 25 | Tse (Ping) Director (Executive) |
BUY | 29.87M | $28.44M | Direct |
| Jul 16, 25 | Tse (Hsin Stephen) Director (Executive) |
BUY | 1.00M | $824.20K | Direct |
| Sep 30, 24 | Tse (Ping) Director (Executive) |
SELL | 13.80M | $6.61M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Cheng (Cheung Ling) |
Director (Executive) | 2.97B | Acquisition |
Tse (Hsin Stephen) |
Director (Executive) | 360.56M | Acquisition |
Tse (Ping) |
Director (Executive) | 1.69B | Acquisition |
Tse (Theresa Y Y) |
Chairman of the Board | 7.75M | Acquisition |
Fundamentals
Market cap$13.33B
Enterprise value$16.66B
Revenue (TTM)$33.70B
Gross profit$27.78B
EBITDA$10.41B
Net income$2.39B
EPS (TTM)$0.02
Free cash flow—
Total cash$27.58B
Total debt$17.17B
Book value / share$0.25
Shares outstanding17.77B
Float8.73B
Short % of float—
Dividend yield2.04%
Beta (5Y)0.62
Valuation & profitability ratios
Trailing P/E37.50
Forward P/E—
PEG ratio1.02
Price / sales—
Price / book2.95
EV / revenue0.49
EV / EBITDA1.60
Gross margin82.43%
Operating margin34.00%
Profit margin7.09%
Return on equity14.07%
Return on assets7.51%
Debt / equity37.13
Current ratio1.63
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $31.83B | $28.87B | $26.20B | $26.03B | +10.3% |
| Operating revenue | $31.83B | $28.87B | $26.20B | $26.03B | +10.3% |
| Cost of revenue | $5.71B | $5.34B | $4.99B | $4.49B | +7.0% |
| Gross profit | $26.13B | $23.53B | $21.21B | $21.54B | +11.0% |
| Research & development | $5.87B | $5.09B | $4.40B | $4.16B | +15.3% |
| Selling, general & admin | $13.14B | $12.16B | $11.07B | $11.71B | +8.0% |
| Total operating expense | $19.23B | $17.20B | $15.12B | $16.06B | +11.8% |
| Operating income | $6.90B | $6.33B | $6.09B | $5.48B | +8.9% |
| Net interest income | $355.28M | $204.45M | -$116.90M | -$233.59M | +73.8% |
| Pre-tax income | $6.94B | $5.28B | $5.41B | $5.21B | +31.6% |
| Tax provision | $1.63B | $492.92M | $797.27M | $696.72M | +230.5% |
| Net income | $2.34B | $3.50B | $2.33B | $2.54B | -33.0% |
| Net income to common | $2.34B | $3.50B | $2.54B | $2.31B | -33.0% |
| Basic EPS | 0.13 | 0.19 | 0.13 | 0.14 | -31.9% |
| Diluted EPS | 0.13 | 0.19 | 0.13 | 0.12 | -32.1% |
| EBIT | $7.22B | $5.57B | $5.91B | $5.64B | +29.6% |
| EBITDA | $8.43B | $6.89B | $6.98B | $6.69B | +22.3% |
| Basic shares | 18.00B | 18.29B | 18.53B | 18.62B | -1.6% |
| Diluted shares | 18.06B | 18.30B | 18.58B | 19.02B | -1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $12.18B | $9.57B | $9.45B | $12.07B | +27.3% |
| Cash & short-term investments | $22.96B | $14.82B | $14.12B | $16.92B | +55.0% |
| Accounts receivable | $5.70B | $4.31B | $3.80B | $3.72B | +32.2% |
| Inventory | $2.26B | $2.37B | $1.99B | $2.33B | -4.9% |
| Total current assets | $34.47B | $24.69B | $23.81B | $25.93B | +39.6% |
| Property, plant & equipment | $10.23B | $10.29B | $9.91B | $9.25B | -0.5% |
| Goodwill & intangibles | $7.05B | $3.06B | $2.91B | $1.91B | +130.4% |
| Total assets | $76.01B | $65.41B | $63.60B | $64.06B | +16.2% |
| Total current liabilities | $25.20B | $19.56B | $22.61B | $20.15B | +28.9% |
| Current debt | $8.40B | $7.60B | $11.14B | $9.66B | +10.4% |
| Long-term debt | $7.58B | $2.00B | $1.07B | $3.93B | +279.8% |
| Total debt | $16.07B | $9.71B | $12.58B | $13.98B | +65.5% |
| Total liabilities | $33.92B | $22.63B | $25.43B | $26.12B | +49.9% |
| Retained earnings | $24.95B | $25.28B | $23.65B | $23.07B | -1.3% |
| Shareholder equity | $30.67B | $31.96B | $30.47B | $29.75B | -4.0% |
| Working capital | $9.27B | $5.13B | $1.20B | $5.78B | +80.7% |
| Net tangible assets | $23.62B | $28.90B | $27.57B | $27.83B | -18.3% |
| Shares issued | 18.76B | 18.79B | 18.80B | 18.81B | -0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Depreciation & amortisation | $1.21B | $1.32B | $1.07B | $1.05B | -8.3% |
| Stock-based compensation | $115.97M | $53.72M | $18.12M | $29.72M | +115.9% |
| Change in working capital | $2.62B | $99.84M | -$430.51M | -$195.59M | +2,528.7% |
| Operating cash flow | $9.29B | $6.62B | $6.07B | $6.27B | +40.5% |
| Capital expenditure | -$1.70B | -$1.39B | -$1.70B | -$1.71B | -22.1% |
| Investing cash flow | -$12.41B | -$1.71B | -$756.98M | -$4.07B | -626.3% |
| Share buybacks | -$110.00M | -$1.25B | -$396.39M | -$867.61M | +91.2% |
| Dividends paid | -$1.50B | -$1.85B | -$632.67M | -$1.27B | +18.6% |
| Financing cash flow | $4.16B | -$6.32B | -$6.55B | -$3.19B | +165.8% |
| Free cash flow | $7.59B | $5.22B | $4.36B | $4.56B | +45.4% |
| End cash position | $7.38B | $6.23B | $7.51B | $8.65B | +18.5% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $12.18B | $11.10B | $9.57B | +9.7% |
| Cash & short-term investments | $22.96B | $19.82B | $14.82B | +15.8% |
| Accounts receivable | $5.70B | $8.15B | $4.31B | -30.1% |
| Inventory | $2.26B | $2.10B | $2.37B | +7.3% |
| Total current assets | $34.47B | $33.82B | $24.69B | +1.9% |
| Property, plant & equipment | $10.23B | $10.05B | $10.29B | +1.8% |
| Goodwill & intangibles | $7.05B | $3.12B | $3.06B | +126.1% |
| Total assets | $76.01B | $74.89B | $65.41B | +1.5% |
| Total current liabilities | $25.20B | $24.85B | $19.56B | +1.4% |
| Current debt | $8.40B | $8.85B | $7.60B | -5.2% |
| Long-term debt | $7.58B | $3.00B | $2.00B | +152.8% |
| Total debt | $16.07B | $11.96B | $9.71B | +34.4% |
| Total liabilities | $33.92B | $29.12B | $22.63B | +16.5% |
| Retained earnings | $24.95B | $28.02B | $25.28B | -10.9% |
| Shareholder equity | $30.67B | $33.37B | $31.96B | -8.1% |
| Working capital | $9.27B | $8.97B | $5.13B | +3.3% |
| Net tangible assets | $23.62B | $30.25B | $28.90B | -21.9% |
| Shares issued | 18.76B | 18.76B | 18.79B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $36.21B | +13.7% |
| Next year | — | — | $38.65B | +6.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders48.66%
Held by institutions23.23%
Institutions holding311
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.64
+17.11% from price
SMA 20
0.63
+18.18% from price
SMA 50
0.63
+19.57% from price
SMA 100
0.67
+12.03% from price
SMA 200
0.76
-1.43% from price
EMA 12
0.65
+15.14% from price
EMA 26
0.64
+17.30% from price
EMA 50
0.64
+16.65% from price
RSI (14)
90.1
Overbought
MACD (12,26,9)
0.01
Hist 0.01
ATR (14)
0.01
1.59% of price
Realised vol 30D
46.1%
Annualised
Bollinger upper
0.70
20, 2σ
Bollinger lower
0.57
20, 2σ
50 / 200 cross
Death
0.63 vs 0.76
Trend bias
Below 200
-1.43%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.07
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
46.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-52.2%
Peak to trough
Max drawdown 5Y
-63.4%
Peak to trough
ATR 14
0.01
1.59% of price
Beta (reported)
0.62
5Y monthly, from filing
Dividends & splits
Forward rate$0.02 / yr
Forward yield2.04%
5-year avg yield1.90%
Payout ratio67.31%
Ex-dividend dateSep 1, 2026
Next pay dateDec 15, 2017
Last split3:2
Split dateJun 4, 2018
SEC filings
Headlines
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
PR Newswire · 4d ago
Sino and AstraZeneca sign licence agreement for TQC3721
Pharmaceutical Technology · 45d ago
European Stocks Close Sharply Lower in Wednesday Trading; Oil Prices Spike as US-Iran War Reignites
MT Newswires · 46d ago
Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday
MT Newswires · 46d ago
AstraZeneca, GSK intensify China ties with Sino Biopharm deals
BioPharma Dive · 46d ago
GSK, Sino Biopharmaceutical Unit Expand Collaboration to Cover Two GSK Respiratory Therapies
MT Newswires · 46d ago
AstraZeneca Acquires Rights for Potential Chinese Respiratory Disease Drug for up to $2.1 Billion
MT Newswires · 46d ago
Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens GSK Partnership
The Wall Street Journal · 46d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.